Your browser doesn't support javascript.
loading
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
Szabados, Bernadett; Kockx, Mark; Assaf, Zoe June; van Dam, Pieter-Jan; Rodriguez-Vida, Alejo; Duran, Ignacio; Crabb, Simon J; Van Der Heijden, Michiel S; Pous, Albert Font; Gravis, Gwenaelle; Herranz, Urbano Anido; Protheroe, Andrew; Ravaud, Alain; Maillet, Denis; Mendez, Maria Jose; Suarez, Cristina; Linch, Mark; Prendergast, Aaron; Tyson, Charlotte; Stanoeva, Diana; Daelemans, Sofie; Rombouts, Miche; Mariathasan, Sanjeev; Tea, Joy S; Mousa, Kelly; Sharma, Shruti; Aleshin, Alexey; Banchereau, Romain; Castellano, Daniel; Powles, Thomas.
Afiliación
  • Szabados B; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Kockx M; CellCarta N V, Wilrijk, Belgium.
  • Assaf ZJ; Genentech, San Francisco, CA, USA.
  • van Dam PJ; CellCarta N V, Wilrijk, Belgium.
  • Rodriguez-Vida A; Hospital del Mar, Barcelona, Spain.
  • Duran I; Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Seville, Spain.
  • Crabb SJ; Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK.
  • Van Der Heijden MS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Pous AF; Institut Catala d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
  • Gravis G; Institut Paoli-Calmettes, Marseille, France.
  • Herranz UA; Hospital Clinico Universitario de Santiago, Santiago De Compostela, Spain.
  • Protheroe A; Churchill Hospital, Oxford, UK.
  • Ravaud A; Department of Medical Oncology, Hopital Saint-Andre, University of Bordeaux-CHU, Bordeaux, France.
  • Maillet D; Hospital Lyon SUD, Lyon, France.
  • Mendez MJ; Reina Sofia University Hospital, Cordoba, Spain.
  • Suarez C; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain.
  • Linch M; UCLH, London, UK.
  • Prendergast A; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Tyson C; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Stanoeva D; CellCarta N V, Wilrijk, Belgium.
  • Daelemans S; CellCarta N V, Wilrijk, Belgium; Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium.
  • Rombouts M; CellCarta N V, Wilrijk, Belgium.
  • Mariathasan S; Genentech, San Francisco, CA, USA.
  • Tea JS; Genentech, San Francisco, CA, USA.
  • Mousa K; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Sharma S; Natera, Inc., San Carlos, CA, USA.
  • Aleshin A; Natera, Inc., San Carlos, CA, USA.
  • Banchereau R; Genentech, San Francisco, CA, USA.
  • Castellano D; Hospital 12 de Octubre, Madrid, Spain.
  • Powles T; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK. Electronic address: thomas.powles1@nhs.net.
Eur Urol ; 82(2): 212-222, 2022 08.
Article en En | MEDLINE | ID: mdl-35577646
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Terapia Neoadyuvante / Anticuerpos Monoclonales Humanizados / ADN Tumoral Circulante Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Eur Urol Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Terapia Neoadyuvante / Anticuerpos Monoclonales Humanizados / ADN Tumoral Circulante Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Eur Urol Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Suiza